论文部分内容阅读
目的:采用Meta分析方法评价葛根素注射剂辅助西医常规治疗脑梗死的有效性及安全性。方法:计算机检索the Cochrane Library、PubMed、Embase、SinoMed、中国期刊全文数据库(CNKI)、中文科技期刊全文数据库(VIP)、万方数据库中有关葛根素注射剂治疗脑梗死的随机对照试验(RCTs),文献检索年限为各数据库建库至2016年10月22日。采用Cochrane风险评估表评价其偏倚风险,提取资料并通过Rev Man 5.3软件进行数据分析。结果:共纳入18个RCTs,累计1 624名患者。Meta分析结果显示,在西医常规治疗的基础上,联用葛根素注射剂可提高脑梗死患者的临床总有效率(RR=1.21,95%CI:1.15~1.26,P<0.000 01)。此外,联用葛根素注射剂也可改善神经功能缺损情况(MD=-5.03,95%CI:-6.88~-3.17,P<0.000 01),影响血液流变学指标等。纳入研究中2个RCTs明确记录未发生明显不良反应,5个RCTs发生了26例不良反应。结论:葛根素射剂辅助西医常规治疗脑梗死具有较好的疗效,但其安全性需进一步探讨。
OBJECTIVE: To evaluate the efficacy and safety of puerarin injection in the conventional treatment of cerebral infarction by Western analysis using Meta analysis. Methods: Randomized controlled trials (RCTs) of puerarin on cerebral infarction in the Cochrane Library, PubMed, Embase, SinoMed, VIP, Wanfang Database were searched by computer. The length of the literature search database for each database until October 22, 2016. The Cochrane Risk Assessment Scale was used to assess the risk of bias, extract data and perform data analysis using Rev Man 5.3 software. Results: A total of 18 RCTs were included, with a total of 1 624 patients. Meta-analysis showed that the combination of puerarin on the basis of routine treatment of western medicine can improve the total effective rate of patients with cerebral infarction (RR = 1.21, 95% CI: 1.15-1.26, P <0.000 01). In addition, puerarin injection can also improve the neurological deficit (MD = -5.03, 95% CI: -6.88 ~ -3.17, P <0.000 01), affecting blood rheology indicators. Two RCTs included in the study clearly documented no significant adverse reactions, and five RCTs developed 26 adverse reactions. Conclusion: puerarin-assisted western medicine routine treatment of cerebral infarction has a good effect, but its safety needs further study.